AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
170 hedge funds and large institutions have $526M invested in AMAG Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 59 reducing their positions, and 37 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 59
9% less funds holding
Funds holding: 187 → 170 (-17)
32% less capital invested
Capital invested by funds: $774M → $526M (-$248M)
46% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 37
55% less call options, than puts
Call options by funds: $3.7M | Put options by funds: $8.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$7.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.25M |
| 3 |
JP Morgan Chase
New York
|
+$5.01M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$4.95M |
| 5 |
BlackRock
New York
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.5M |
| 2 |
Morgan Stanley
New York
|
-$6.69M |
| 3 |
Goldman Sachs
New York
|
-$6.03M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.01M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
-$5.49M |
AMAG Hedge Fund Activity: Q4 2017 in Review
170 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2017, worth a combined $526M — down 32% from $774M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of AMAG and 20 opened new positions — a net loss of 17 holders — while 59 trimmed existing stakes and 64 added.
The largest buyer was State Street, adding an estimated $7.54M. The largest seller was Millennium Management, cutting an estimated $13.5M.
- 170 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q4 2017, down from 187 in Q3 2017.
- Funds reported $526M of AMAG Pharmaceuticals stock for Q4 2017, down 32% quarter-over-quarter.
- 20 funds opened new AMAG Pharmaceuticals positions in Q4 2017 and 37 closed out, a net change of -17 holders.
- The largest AMAG Pharmaceuticals buyer in Q4 2017 was State Street, an estimated $7.54M added.
- The largest AMAG Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q4 2017.